Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003572priorityCriticalpatent/ECSP003572A/en
Publication of ECSP003572ApublicationCriticalpatent/ECSP003572A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Nuevos adrógenos oralmente activos son derivados de A14-nandrolona 7-A-sustituidos. Los compuestos satisfacen la fórmula general: (gráfico), donde R1 es O, (H;H), (H,OR), NOR, siendo R hidrógeno, (C1-6) alquilo o (C1-6) acilo; R2 se selecciona del grupo consistente en (C2-4) alquilo, (C2-4) alquenilo o (C2-4) alquinilo, cada uno opcionalmente sustituido por halógeno; o R2 es ciclopropilo o ciclopropenilo, cada uno opcionalmente sustituido por (C1-2) alquilo o halógeno; R3 es hidrógeno, (C1-2) alquilo halógeno; R3 es hidrógeno (C1-2) alquilo o etinilo; R4 es (C1-2) alquilo; R5 es hidrógeno o (C1-15) acilo; y las lineas de puntos indican enlaces opcionales.Novel orally active adrogens are 7-A-substituted A14-nandrolone derivatives. The compounds satisfy the general formula: (graph), where R1 is O, (H; H), (H, OR), NOR, where R is hydrogen, (C1-6) alkyl or (C1-6) acyl; R2 is selected from the group consisting of (C2-4) alkyl, (C2-4) alkenyl, or (C2-4) alkynyl, each optionally substituted by halogen; or R2 is cyclopropyl or cyclopropenyl, each optionally substituted by (C1-2) alkyl or halogen; R3 is hydrogen, (C1-2) alkyl halogen; R3 is hydrogen (C1-2) alkyl or ethynyl; R4 is (C1-2) alkyl; R5 is hydrogen or (C1-15) acyl; and the dotted lines indicate optional links.
ECSP0035722000-07-132000-07-13
ORALLY ACTIVE ANDROGENS
ECSP003572A
(en)
NEW USEFUL HETEROCICLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Heterocyclic compound containing nitrogen atoms having selective neurokinin anatgonist effect pharmaceutical compositions containing them and their use